Summary
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029.
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit.
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company's initial development focus while also discussing ongoing work in non-muscle invasive bladder cancer.
Aura Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 31 | $244.99 | $221.65 | -$23.34 | -9.53% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 30,316 | $215,240 | $242,224.84 | $26,984.84 | 12.54% |
| BG Bart Gancher Intech Investment Management LLC | 11,521 | $67,995.37 | $92,052.79 | $24,057.42 | 35.38% |
| PEC Philip E. Channen Water Island Capital LLC | 60,000 | $426,000 | $461,400 | $35,400 | 8.31% |
 Point72 Asset Management LP Point72 Asset Management LP | 17,864 | $97,358.67 | $137,374.16 | $40,015.49 | 41.1% |
Aura Biosciences Inc. (AURA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aura Biosciences Inc. ever had a stock split?
Aura Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Natalie C. Holles CEO | NASDAQ (NMS) Exchange | 05153U107 CUSIP |
| US Country | 113 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative precision immunotherapies for the treatment of solid tumors. Established in 2009, the company leverages a proprietary platform that uses virus-like particles (VLPs) to target solid tumors effectively. These VLPs can be conjugated with drugs or loaded with nucleic acids to create highly specific virus-like drug conjugates (VLDCs). The headquarters of the company is located in Boston, Massachusetts, symbolizing its position within a hub of biotechnological innovation and development. Aura Biosciences is dedicated to furthering the field of cancer treatment through the advancement of its cutting-edge therapeutic approaches.
Products and Services
-
Bel-Sar
Bel-Sar is Aura Biosciences' lead candidate, currently in late-stage clinical development, primarily targeting the treatment of primary choroidal melanoma, a type of eye cancer. Utilizing the company's unique platform, bel-sar offers a novel approach to targeting and treating this challenging condition. Further, bel-sar is being explored for its potential in other ocular oncology indications, demonstrating the versatility and broad application of the technology. In addition to its application in eye cancers, bel-sar is also in early-stage clinical development for bladder cancer. This expansion into bladder cancer signifies the company's strategy to explore bel-sar's efficacy and safety in a range of solid tumors, offering a possible alternative to bacillus calmette-guérin (BCG) therapy. BCG therapy is currently the standard treatment for certain early-stage bladder cancers, but it can be associated with significant side effects and limitations. Aura Biosciences aims to provide a more targeted and potentially safer alternative through the development of bel-sar.
